gov.ukPharma tariffsUK hikes drug prices after pharma exodusAfter the withdrawal of investment pledges totalling £2bn by pharmaceutical companies — seeking to offset lower US revenue by raising UK prices — the British government has now caved in and signed … more ➔
EIB, Oscar RomanoFinancing/PartneringAngelini Ventures and EIB launch joint start-up financingThe European Investment Bank (EIB) and Angelini Ventures, the corporate venture capital arm of Angelini Industries, have signed an agreement to jointly provide €150m over the next six years to support … more ➔
adobe.stock.com - CathyIndustrial BiotechEU Commission presents new bioeconomy strategyA month after China publicly revealed its bioeconomy priorities under its 15th Five Year Plan, the European Commission released an updated EU Bioeconomy Strategy — and the contrast could hardly be … more ➔
freshidea / Adobe StockImmuno-oncologyVentuno Biotech Secures €3m to Power Next-Gen Cancer ImmunotherapiesLyon-based Ventuno Biotech secures fresh backing to accelerate its preclinical pipeline of first-in-class immuno-oncology assets. more ➔
adobe.stock.com - ipopbaAlzheimer'sNovo Nordisk’s semaglutide fails in Alzheimer’sNovo Nordisk’s semaglutide has failed to reduce the cognition deficit in two Phase III Alzheimer’s trials, dimming GLP-1 hopes. Anti-amyloid and combination therapies remain key for slowing decl … more ➔
Gilead ScienceDealGilead acquires Sprint Bioscience TREX1 programmeSprint Bioscience AB has sold its preclinical TREX1 first-in-class cancer program to Gilead for up to US$414m, validating its fragment-driven small-molecule out-licensing business model. more ➔
stock.adobe.photo.com/Popelniushka PartnershipAGC Biologics to manufacture dual AAV therapies for AAVantgardeAccording to a new deal, AGC Biologics wil manufacture AAVantgarde’s dual AAV gene therapies for inherited retinal diseases using the high-yield BravoAAV™ suspension platform. more ➔
stock.adobe.com/Sadushi NeurodegenerationMelatonin: a promising new approach in Alzheimer’s treatmentMelatonin shows promise in Alzheimer’s treatment by restoring circadian rhythms and reducing neurodegenerative symptoms, researchers have demonstrated in a groundbreaking study. more ➔
RocheBreast cancerGiredestrant demonstrates efficacy in early-stage breast cancerRoche has reported that its selective estrogen receptor degrader (SERD), giredestrant, has demonstrated significant clinical benefit in pivotal Phase III trials for adjuvant early-stage ER-positive, … more ➔
adobe.stock.photos - Yurii Kibalnik FinancingAvanzanite secures €32m Series A fundingDutch Avanzanite Biosciences NV has secured €32 m in a Series A financing round from MVM Partners to scale orphan drug commercialisation across Europe. more ➔
gov.uk
EIB, Oscar Romano
adobe.stock.com - Cathy
freshidea / Adobe Stock
adobe.stock.com - ipopba
Gilead Science
stock.adobe.photo.com/Popelniushka 
stock.adobe.com/Sadushi 
Roche
adobe.stock.photos - Yurii Kibalnik